PI3K/PTEN/mTOR pathway dynamic tracking and prognostic value in HR+/HER2− BC patients with residual...
PI3K/PTEN/mTOR pathway dynamic tracking and prognostic value in HR+/HER2− BC patients with residual disease after neoadjuvant chemotherapy: a cohort study
About this item
Full title
Author / Creator
Publisher
England: BMJ Publishing Group Ltd and Association of Clinical Pathologists
Journal title
Language
English
Formats
Publication information
Publisher
England: BMJ Publishing Group Ltd and Association of Clinical Pathologists
Subjects
More information
Scope and Contents
Contents
AimsHormone receptor-positive (HR)+/HER2− breast cancer (BC) is highly heterogeneous, with PI3K/PTEN/mTOR pathway alterations emerging as possible players within this complexity. We longitudinally tracked PI3K/PTEN/mTOR pathway dynamics from baseline biopsy to residual disease (RD)—and to metastases in case of relapse—in HR+/HER2− BC patients recei...
Alternative Titles
Full title
PI3K/PTEN/mTOR pathway dynamic tracking and prognostic value in HR+/HER2− BC patients with residual disease after neoadjuvant chemotherapy: a cohort study
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_journals_3106895723
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_3106895723
Other Identifiers
ISSN
0021-9746,1472-4146
E-ISSN
1472-4146
DOI
10.1136/jcp-2023-208856
